Natera jumps as new analyst coverage and higher targets revive Signatera momentum trade
Natera shares rose about 3% as fresh sell-side coverage and higher price targets rekindled bullish sentiment around its Signatera-driven growth outlook. Recent notes highlighted sustained oncology momentum and reinforced views that 2026 growth can extend beyond the company’s strong 2025 finish.
1) What’s moving the stock
Natera (NTRA) is moving higher as investors react to renewed Wall Street optimism in recent days, including a research initiation at William Blair and incremental target increases from other firms that have recently reiterated bullish views. The latest wave of commentary has emphasized durability in Natera’s growth narrative—particularly in oncology—helping support demand for the shares in today’s session. (williamblair.com)
2) Why the Street is leaning bullish
Recent analyst commentary has continued to center on Signatera (molecular residual disease testing) as a key driver, with the broader message that momentum that built into late 2025 can carry through 2026. In parallel, Natera’s earlier updates around strong 2025 performance and its 2026 revenue outlook continue to underpin the growth framing being used by bulls. (investor.natera.com)
3) What investors will watch next
After a sentiment-driven lift, the next leg typically depends on tangible catalysts: quarterly execution versus expectations, any updates that further clarify volume growth and mix in oncology, and how confidently management reiterates or raises its full-year outlook. With targets in the market extending well above current levels, investors will also be watching whether the company can keep narrowing losses/cash burn while sustaining high growth rates. (marketbeat.com)